Tag Archives: Mary Bono Mack

Bono Mack backs tamper-proof painkiller legislation

Rep. Mary Bono Mack, R-Ca., has introduced legislation that would require pharmaceutical companies to make new opiate-based pills tamper-resistant. Bono Mack, who is co-chairman of the Congressional Caucus on Prescription Drug Abuse, says the “Stop the Tampering of Prescription Pills” (STOPP) Act would mandate that the FDA inform companies that refuse to manufacture tamper-proof versions to reformulate or withdraw their drug from the market.

But already-existing tamper-proof versions of drugs like OxyContin haven’t necessarily curbed the abuse epidemic. Many painkiller addicts have found ways to get their fix from such versions, or have switched to heroin.

Among Bono Mack’s other pending proposals are the Stop Oxy Abuse Act, which would restrict the use of any pain-relief drug containing oxycodone to “the relief of severe-only instead of moderate-to-severe pain,” and the Ryan Creedon Act of 2011 would require anyone who prescribes controlled substances to be educated on the risks such drugs pose to patients before they can register with the U.S. Drug Enforcement Administration. DEA registration is already required by federal law. Unlike President Barack Obama’s recent plan to curb prescription drug abuse – which allows pharmaceutical companies themselves to “educate” doctors on the risks of their products – the bill specifies that this training should be provided by a medical society, a state medical licensing board, an accredited continuing education provider, or “another organization that the Secretary [of Health and Human Services] determines is appropriate for providing such training or certification.”

Posted in Informational, Pharmaceutical Industry, Policy & Regulation | Tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

Mack resumes painkiller regulation efforts

Rep. Mary Bono Mack, R-Ca., is resuming a series of Congressional hearings on prescription drug abuse that began last year. While Mack says painkillers like oxycodone have become too available, some patient advocates and addiction experts contend that a congressional committee is not the appropriate forum for addressing the conditions under which such powerful drugs should be prescribed.

Among Mack’s proposals are the Stop Oxy Abuse Act, which would restrict the use of any pain-relief drug containing oxycodone to “the relief of severe-only instead of moderate-to-severe pain,” and the Ryan Creedon Act of 2011 would require anyone who prescribes controlled substances to be educated on the risks such drugs pose to patients before they can register with the U.S. Drug Enforcement Administration. DEA registration is already required by federal law. Unlike President Barack Obama’s recent plan to curb prescription drug abuse – which allows pharmaceutical companies themselves to “educate” doctors on the risks of their products – the bill specifies that this training should be provided by a medical society, a state medical licensing board, an accredited continuing education provider, or “another organization that the Secretary [of Health and Human Services] determines is appropriate for providing such training or certification.”

Posted in Informational, Policy & Regulation | Tagged , , , , , , , , , , , , | Leave a comment